Market Cap
$5.6B
TVTX
Travere Therapeutics, Inc.
$56.93 ▲ +0.14%
Prev close $56.85Market cap$5.6B
ConsensusStrong Buy
12-mo target$75.21 (+32.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (7 insiders)High Impact Filing (7/10)33 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TVTX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$4.3B
Inst. Activity
33 buys / 17 sells
Insider Activity
$0.00 buy / $58.6M sell
Insider Net $
-$58.6M
Social Sentiment
67° Warm
SEC Reports
16
Price chart 30d -14.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: TVTX — 71.7% short (0.5M / 0.7M)
Short: 511,716 | Exempt: 800 | TRF Vol: 713,291 | Short Ratio: 71.7% | Off-exchange volume (dark poo
Sep 17, 2026 Insider
Dube Eric M sold 101,691 shares
CHIEF EXECUTIVE OFFICER @ $64.59 ($6.6M)
Sep 17, 2026 Insider
Dube Eric M acquired via exercise 108,493 shares
CHIEF EXECUTIVE OFFICER @ $23.34 ($2.5M)
Sep 17, 2026 Insider
Jul 9, 2026 SEC Dube Eric M sold 6,802 shares
CHIEF EXECUTIVE OFFICER @ $64.95 ($441.8K)
Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected F
8-K — Impact 2/10
Jul 1, 2026 Event
HSR Early Termination: Travere Therapeutics, Inc.; Everest Medicines Limited
The FTC granted early termination of the HSR Act waiting period for a transaction involving Travere
Jun 30, 2026 Inst.
FMR LLC — TRIM
7,096,614 shares ($403.2M)
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — DOUBLED
4,568,341 shares ($259.5M)
Analyst ratings buy % +4.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Sep 22, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 10, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 6, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Aug 5, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 5, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 5, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Aug 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Jul 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Jun 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% | |
| Mar 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% | |
| Feb 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% |
Price targets
Where 14 covering analysts think TVTX trades over the next 12 months.
$75.21 +32.1% upside Strong Buy
Current$56.93 Low$62.00 Median$75.50 High$90.00 14 analysts
$62.00$90.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 3 bullish, 4 bearish, 0 mixed, 9 neutral · avg impact 4.3/10.
NEUTRAL8-K2/10
Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2
Jul 9, 2026
NEUTRAL8-K2/10
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effect
Jun 16, 2026
NEUTRALCLUSTER2/10
Two directors of Travere Therapeutics (TVTX) exercised stock options and immediately sold the result
Jun 16, 2026
NEUTRAL1442/10
Director Timothy Coughlin filed a Form 144 to sell 10,000 common shares of Travere Therapeutics (TVT
Jun 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: TVTX — 71.7% short (0.5M / 0.7M)
Short: 511,716 | Exempt: 800 | TRF Vol: 713,291 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of
Sep 30, 2026
short_volume
Short Volume: TVTX — 84.1% short (0.5M / 0.6M)
Short: 532,527 | Exempt: 2 | TRF Vol: 633,246 | Short Ratio: 84.1% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: TVTX — 73.4% short (0.4M / 0.6M)
Short: 446,770 | Exempt: 0 | TRF Vol: 608,495 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: TVTX — 63.2% short (0.3M / 0.5M)
Short: 343,199 | Exempt: 0 | TRF Vol: 542,848 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.52 | $-0.57–$1.16 | -11.7% | +1.7% | 2↑ 0↓ | $0.2B | 8 |
| Next Q | $1.14 | $0.68–$2.03 | 208.5% | +0.0% | 4↑ 1↓ | $0.2B | 8 |
| Current FY | $1.74 | $0.96–$2.95 | 91.4% | +0.4% | 2↑ 2↓ | $0.7B | 8 |
| Next FY | $5.67 | $3.50–$6.95 | 225.7% | +3.3% | 3↑ 3↓ | $1.1B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.521 | — |
| 7d ago | $0.521 | — |
| 30d ago | $0.512 | +0.009 |
| 60d ago | $0.398 | +0.123 |
| 90d ago | $0.396 | +0.125 |
Institutional ownership
Which big funds own TVTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.3B total value (76,235,349 shares) as of 2026-Q2. Top holders: Jupiter, BlackRock,, FMR. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Jupiter Topco LLC | 11,324,191 | $643.3M | 14.8% | — |
| BlackRock, Inc. | 8,020,663 | $455.7M | 10.5% | — |
| FMR LLC | 7,096,614 | $403.2M | 9.3% | TRIM -35.3% |
| BANK OF AMERICA CORP /DE/ | 4,568,341 | $259.5M | 6.0% | DOUBLED +239.6% |
| STATE STREET CORP | 4,256,224 | $241.8M | 5.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,108,694 | $233.4M | 5.4% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2,812,514 | $159.8M | 3.7% | — |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,569,356 | $146.0M | 3.4% | DOUBLED +163.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,371,887 | $134.8M | 3.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,833,079 | $104.1M | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | TRIM | 10,967,967 | 7,096,614 | -35.3% | $403.2M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,345,111 | 4,568,341 | +239.6% | $259.5M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 977,000 | 2,569,356 | +163.0% | $146.0M |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 1,022,272 | 1,533,080 | +50.0% | $87.1M |
| Qube Research & Technologies Ltd | DOUBLED | 669,159 | 1,443,230 | +115.7% | $82.0M |
| D. E. Shaw & Co., Inc. | ADD | 836,544 | 1,440,469 | +72.2% | $81.8M |
| MARSHALL WACE, LLP | DOUBLED | 178,536 | 1,333,207 | +646.7% | $75.7M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 109,382 | 1,156,960 | +957.7% | $65.7M |
| JANE STREET GROUP, LLC | DOUBLED | 302,280 | 938,699 | +210.5% | $53.3M |
| Fiera Capital Corp | TRIM | 900,868 | 516,997 | -42.6% | $29.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$58.6M — $0.00 bought, $58.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 101,691 | $64.59 | $6.6M |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | EXERCISE | 108,493 | $23.34 | $2.5M |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 6,802 | $64.95 | $441.8K |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | EXERCISE | 8,282 | $22.40 | $185.5K |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | SELL | 8,282 | $65.07 | $538.9K |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | EXERCISE | 195,841 | $23.34 | $4.6M |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 99,716 | $63.26 | $6.3M |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 96,125 | $63.64 | $6.1M |
| Sep 16, 2026 | ROTE WILLIAM E. | Chief Research Officer | EXERCISE | 350 | $17.96 | $6.3K |
| Sep 16, 2026 | ROTE WILLIAM E. | Chief Research Officer | EXERCISE | 55,000 | $15.46 | $850.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TVTX.
Shares short
12,955,933
Settlement Sep 15, 2026
Change vs prior
+7.9%
Semi-monthly cycle
Days to cover
10.4
At avg daily volume
Of shares outstanding
≈13.7%
Estimate — not % of float
All TVTX filing & press-release reports (16)
- 8-K reportJul 9, 2026
- 8-K reportJun 16, 2026
- CLUSTER reportJun 16, 2026
- 144 reportJun 12, 2026
- 8-K reportJun 2, 2026
- 144 reportMay 15, 2026
- CLUSTER reportMay 7, 2026
- 144 reportMay 5, 2026
- 144 reportMay 4, 2026
- CLUSTER reportApr 23, 2026
- CLUSTER reportApr 16, 2026
- CLUSTER reportApr 16, 2026
- 144 reportApr 15, 2026
- 8-K reportApr 14, 2026
- 144 reportApr 1, 2026
- INST-CLUSTER reportFeb 28, 2026